We are live on ! Find out more
NIP

Nicholas Investment Partners Portfolio holdings

AUM $1.39B
1-Year Est. Return 97.11%
This Fund
S&P 500
This Quarter Est. Return
+25.16%
1 Year Est. Return
+97.11%
3 Year Est. Return
+361.61%
5 Year Est. Return
+496.81%
10 Year Est. Return
+3,647.83%
AUM
$1.46B
AUM Growth
+$147M
Cap. Flow
-$82.7M
Cap. Flow %
-5.66%
Top 10 Hldgs %
25.13%
Holding
215
New
28
Increased
57
Reduced
41
Closed
25

Top Buys

Rank Stock Value
1
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$31.1M
2
MRK icon
Merck
MRK
+$27.8M
3
MIRM icon
Mirum Pharmaceuticals
MIRM
+$24.3M
4
IMGN
Immunogen Inc
IMGN
+$14.5M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$14.1M

Top Sells

Rank Stock Value
1
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$29.3M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$28.4M
3
UTHR icon
United Therapeutics
UTHR
+$26.8M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$25.8M
5
PODD icon
Insulet
PODD
+$23.6M

Sector Composition

Rank Sector Weight
1 Healthcare 53.92%
2 Technology 13.34%
3 Industrials 8.74%
4 Consumer Discretionary 4.85%
5 Energy 4.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADBE icon
151
Adobe
ADBE
$105B
$383K 0.03%
783
-722
-48% -$291K
ULTA icon
152
Ulta Beauty
ULTA
$24.3B
$375K 0.03%
797
-238
-23% -$117K
BILL icon
153
BILL Holdings
BILL
$4.78B
$337K 0.02%
+2,887
New +$274K
POST icon
154
Post Holdings
POST
$3.57B
$326K 0.02%
3,760
– –
XYZ
155
Block Inc
XYZ
$47.5B
$324K 0.02%
4,873
– –
ORCL icon
156
Oracle
ORCL
$423B
$303K 0.02%
+2,544
New +$263K
IMCR icon
157
Immunocore
IMCR
$1.73B
$282K 0.02%
+4,700
New +$268K
TEAM icon
158
Atlassian
TEAM
$37.8B
$271K 0.02%
1,614
-3,408
-68% -$546K
SLGCW
159
DELISTED
SomaLogic, Inc. Warrant
SLGCW
$6.79K ﹤0.01%
27,148
– –
ABBV icon
160
AbbVie
ABBV
$435B
– –
-22,800
Closed -$3.63M
APTV icon
161
Aptiv
APTV
$10.3B
– –
-18,234
Closed -$2.05M
ASO icon
162
Academy Sports + Outdoors
ASO
$2.98B
– –
-47,870
Closed -$3.12M
BAC icon
163
Bank of America
BAC
$442B
– –
-30,000
Closed -$858K
BJ icon
164
BJs Wholesale Club
BJ
$12.3B
– –
-103,012
Closed -$7.84M
BOOT icon
165
Boot Barn
BOOT
$4.95B
– –
-50,818
Closed -$3.89M
BURL icon
166
Burlington
BURL
$23.2B
– –
-3,545
Closed -$716K
CYBR
167
DELISTED
CyberArk
CYBR
– –
-15,719
Closed -$2.33M
FANG icon
168
Diamondback Energy
FANG
$52.7B
– –
-2,856
Closed -$386K
FIVN icon
169
FIVE9
FIVN
$2.54B
– –
-55,672
Closed -$4.02M
FOXF icon
170
Fox Factory Holding Corp
FOXF
$886M
– –
-31,363
Closed -$3.81M
KMPR icon
171
Kemper
KMPR
$1.68B
– –
-67,971
Closed -$3.72M
MC icon
172
Moelis & Co
MC
$4.94B
– –
-72,793
Closed -$2.8M
MDGL icon
173
Madrigal Pharmaceuticals
MDGL
$11.8B
– –
-117,047
Closed -$28.4M
MGRC icon
174
McGrath RentCorp
MGRC
$2.92B
– –
-41,362
Closed -$3.86M
MTDR icon
175
Matador Resources
MTDR
$6.09B
– –
-60,413
Closed -$2.88M
4 5 6
7
8

Similar funds

FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
1CP
1607 Capital Partners Richmond, Virginia $1.39B AUM 8.35% 1-Year Est. Return
OCM
Opti Capital Management New York $1.39B AUM 0% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
TA
Trivest Advisors Hong Kong $1.39B AUM 273.03% 1-Year Est. Return
AU
Algebris (UK) London, United Kingdom $1.38B AUM 3.87% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
BCP
Blue Chip Partners Farmington Hills, Michigan $1.39B AUM 22.32% 1-Year Est. Return

Nicholas Investment Partners's Q2 2023 Portfolio in Review

As of Q2 2023, Nicholas Investment Partners held 215 positions worth $1.46B, up 11% from $1.32B the previous quarter. Its ten largest holdings account for 25% of the portfolio.

Nicholas Investment Partners withdrew a net $82.7M in Q2 2023, closing 25 positions and reducing 41 holdings. Its most notable exit was Prometheus Biosciences, Inc. Common Stock, an estimated $29.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 54% of assets, up from 53% a quarter earlier, followed by Technology and Industrials.

Against the trend, Nicholas Investment Partners opened a new position in Intra-Cellular Therapies Inc. worth $31.6M.

  • Nicholas Investment Partners's largest Q2 2023 buy was Intra-Cellular Therapies Inc.: 499,503 shares worth $31.6M.
  • Nicholas Investment Partners added most to Xenon Pharmaceuticals in Q2 2023, an estimated $14.1M increase.
  • Nicholas Investment Partners's biggest Q2 2023 reduction was Lantheus, cutting an estimated $9.72M.
  • Nicholas Investment Partners fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $29.3M.
  • Nicholas Investment Partners's ten largest holdings make up 25% of its $1.46B portfolio in Q2 2023.
  • Nicholas Investment Partners opened 28 new positions and closed 25 in Q2 2023.
  • Nicholas Investment Partners's portfolio value rose 11% quarter-over-quarter to $1.46B.

Based on Nicholas Investment Partners's 13F filing for Q2 2023, filed 10 Aug 2023.